|
|
|
| Predictive Value of Lung Ultrasound Scoring for Poor Prognosis in Neonatal Respiratory Distress Syndrome |
| GUO Fengjuan, LIANG Guosheng, BIAN Fubao, GE Jianli, ZHANG Zhiling, LI Kaizhen |
| Department of Ultrasound, Puyang Oilfield General Hospital, Puyang Henan 457000 |
|
|
|
|
Abstract 【Objective】To investigate the predictive value of lung ultrasound scoring (LUS) for poor prognosis in neonatal respiratory distress syndrome (NRDS). 【Methods】A total of 50 neonates with neonatal respiratory distress syndrome admitted to Puyang Oilfield General Hospital from January 2022 to October 2025 were enrolled. According to the prognosis after 7 days of treatment, the patients were divided into the good prognosis group (n=34) and the poor prognosis group (n=16). General data were compared between the two groups. Spearman rank correlation analysis was used to evaluate the correlations of LUS with blood routine parameters, blood gas analysis parameters, and clinical grading. Receiver operating characteristic (ROC) curve analysis was used to evaluate the predictive value of LUS for poor prognosis in NRDS after 7 days of treatment. 【Results】LUS was negatively correlated with white blood cell count (P<0.05), but showed no correlation with neutrophil percentage, lymphocyte percentage, pre-treatment pH, arterial partial pressure of oxygen (PaO2), or clinical grading (all P>0.05). Among the 50 neonates, 34 had a good prognosis (the good prognosis group) and 16 had a poor prognosis (the poor prognosis group). There were statistically significant differences between the two groups regarding body length, body weight, whether ventilator use duration ≥7 days, LUS, and oxygenation index (all P<0.05). There were no statistically significant differences between the two groups in terms of 1-minute Apgar score, white blood cell count, neutrophil percentage, lymphocyte percentage, CRP, pre-treatment pH, or PaO2 (all P>0.05). The area under the ROC curve of LUS for predicting poor prognosis in NRDS after 7 days of treatment was 0.692, with a sensitivity of 27.00% and a specificity of 71.00%. 【Conclusion】LUS shows no significant correlation with clinical grading in neonatal respiratory distress syndrome, but it has important clinical value in predicting poor prognosis in neonatal respiratory distress syndrome.
|
|
Received: 25 December 2025
|
|
|
|
|
|
[1] Mohammadi A, De Luca D, Gauda E B.Characteristics, triggers, treatments, and experimental models of neonatal acute respiratory distress syndrome[J].Am J Physiol Lung Cell Mol Physiol, 2025,328(4):L512-L525. [2] Wang L, Wang D G, Zhang T L, et al.The role of immunometabol-ism in macrophage polarization and its impact on acute lung injury/acute respiratory distress syndrome[J].Front Immunol, 2023,14:1117548. [3] Li X H, Liu H. Expression and prognostic value of MIP-1α in neonatal acute respiratory distress syndrome[J]. Am J Transl Res, 2022, 14(11): 7889-7897. [4] 刘敬, 胡才宝. 新生儿呼吸窘迫综合征超声诊断与分度专家共识[J].中国小儿急救医学, 2021,28(7):545-550. [5] Sweet D G, Carnielli V P, Greisen G,et al. European Consensus Guidelines on the Management of Respiratory Distress Syndrome: 2022 Update[J].Neonatology,2023,120(1):3-23. [6] 邵肖梅,叶鸿瑁,邱小汕.实用新生儿学[M]. 4版.北京:人民卫生出版社, 2011: 396-399. [7] Shatla E S,Prashanth G P,Aguiar R,et al. Neonatal stridor infamilialcongenital Laryngealparalysis(plottsyndrome): acasestudy inanomani family[J]. Oman Med J, 2017, 32(6):515-517. [8] 邢丽云, 朱晓芳. 441例新生儿呼吸窘迫综合征临床特征及影响因素分析[J].中国妇幼保健, 2023, 38(17) : 3312-3315. [9] Song H, Lu H N, Chen X, et al. MiR-216a-3p promotes differentiation of BMMSCs into ACE Ⅱ cells via Wnt/β-catenin pathway[J]. Eur Rev Med Pharmacol Sci, 2018, 22(22): 7849-7857. [10] 赵岩,李守龙,王国兴,等.超声介入联合抗生素治疗肺炎克雷伯菌肝脓肿临床分析[J].中国医师杂志,2021,23(10):1457-1460. [11] 高阳,李聪,汝艳辉,等.肺部高频超声评分联合血清IL-6、CRP、PCT水平评估新生儿呼吸窘迫综合征患儿预后的价值[J].中国医师杂志,2024,26(5):717-721. [12] 苗晓霞,才海燕,高彩云,等.新生儿呼吸窘迫综合征极低出生体重儿并发支气管肺发育不良高危因素分析[J].中国实验诊断学,2022,26(5):648-652. [13] 郭建康,张彬,梁优.高频肺部超声评分对新生儿呼吸窘迫综合征预后的预测分析[J].影像科学与光化学,2022,40(5):1123-1127. [14] 张进.肺部超声在肺结核诊断中的应用价值[J].医学临床研究,2025, 42(3):474-476. [15] 周蕾,李令民,朱国英.肺部超声新评分法在新生儿呼吸窘迫综合征用肺泡表面活性物质治疗中的临床疗效[J].智慧健康,2023,9(35):9-12. |
|
|
|